ArticleFrontiers in endocrinology2021
Feminizing Hormone Therapy Prescription Patterns and Cardiovascular Risk Factors in Aging Transgender Individuals in Australia.
Article in Frontiers in endocrinology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 15 citations in OpenAlex.
- Cardiometabolic diseases in transgender populations.Cardiovascular diabetology. Endocrinology reports · 2026Review
- Therapeutic Issues Associated with Gender-Affirming Hormone Therapy in Transgender Individuals: A Systematic Review Relevant to Community Pharmacy Practice.Pharmacy (Basel, Switzerland) · 2026Review
- Gender affirmation among transgender and gender-diverse people in middle age and late life: a scoping review.The Gerontologist · 2026Article
- Equitable aging in health framework: a multi-systems and multilevel approach to health challenges and supports for transgender older adults.Innovation in aging · 2025Article
- Transgender Women With Suppressed Testosterone Display Lower Burden of Coronary Disease Than Matched Cisgender Men.Journal of the Endocrine Society · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Context: The safety and efficacy of feminizing hormone therapy in aging transgender (trans) individuals is unclear. Current recommendations suggest transdermal estradiol beyond the age of 45 years, especially if cardiometabolic risk factors are present. Objective: To evaluate feminizing hormone therapy regimens and cardiovascular risk factors in aging trans individuals. Design: Retrospective cross-sectional analysis. Setting: Primary care and endocrine specialist clinic in Melbourne, Australia. Participants: Trans individuals on feminizing therapy for ≥6 months. Main Outcomes Measures: Feminizing hormone regimens and serum estradiol concentrations by age group: (a) ≥45 years, (b) <45 years, and prevalence of cardiometabolic risk factors in individuals ≥45 years. Results: 296 individuals were stratified by age group: ≥45 years ( Conclusions: A greater proportion of trans individuals ≥45 years of age were treated with transdermal estradiol. Of those who received oral estradiol, the median dose was lower. This is important given the high prevalence of cardiometabolic risk factors in this age group, however cardiovascular risk management guidelines in this demographic are lacking.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.